NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. “We know that many patients struggle with eyelid ...
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with ...
Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results